Salarius Pharmaceuticals Inc. [SLRX] stock is up 45.95 while the S&P 500 has fallen -0.06% on Thursday, 12/03/20. While at the time of this article, SLRX ATR is sitting at 0.09, with the beta value at 1.89. This stock’s volatility for the past week remained at 20.77%, while it was 11.08% for the past 30-day period. SLRX has risen $0.34 from the previous closing price of $0.74 on volume of 10.89 million shares.
On 17, November 2020, Salarius Pharmaceuticals to Participate in A.G.P.’s Virtual Healthcare Symposium. According to news published on Yahoo Finance, Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors and other cancers, today announced its chief executive officer, David Arthur, will participate in A.G.P.’s Virtual Healthcare Symposium on Thursday, November 19, 2020.
Analyst Birdseye View:
Before that, on April 27, 2020, Ladenburg Thalmann Recapitulated a Buy rating and elevated its amount target to $3.80.
In the past 52 weeks of trading, this stock has oscillated between a low of $0.56 and a peak of $4.98. Right now, the middling Wall Street analyst 12-month amount mark is $4.40. At the most recent market close, shares of Salarius Pharmaceuticals Inc. [NASDAQ:SLRX] were valued at $1.08.
Salarius Pharmaceuticals Inc. [NASDAQ:SLRX] most recently reported quarterly sales of 1.38 billion, which represented growth of 55.60%. This publicly-traded organization’s revenue is $433,132 per employee, while its income is -$867,262 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -57.14, -69.86, -81.17 and -69.86 respectively.
The Principal structure of this organization shows its whole liability to whole principal at 4.53 and the whole liability to whole assets at 3.62.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 0.7900 points at 1st support level, the second support level is making up to 0.5000. But as of 1st resistance point, this stock is sitting at 1.3000 and at 1.5200 for 2nd resistance point.
Salarius Pharmaceuticals Inc. [SLRX] reported its earnings at -$0.1 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.1/share signifying the difference of 0 and 0.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.13 calling estimates for -$0.16/share with the difference of 0.03 depicting the surprise of 18.80%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Salarius Pharmaceuticals Inc. [NASDAQ:SLRX] is 5.70. Likewise, the Quick ratio is also the same, showing Cash ratio at 1.13. Now if looking for a valuation of this stock’s amount to sales ratio it’s 3.57 and it’s amount to book ratio is 1.61.
The most recent insider trade was by HANISH ARNOLD C, Director, and it was the purchase of 4000.0 shares on Aug 21. Arthur David J., the Chief Executive Officer, completed a purchase of 2000.0 shares on Aug 19. On Aug 17, Rosenblum Mark J, Exec VP Finance, CFO, completed a purchase of 5000.0 shares.